These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

359 related items for PubMed ID: 27502396

  • 1. uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R.
    Huber MC, Mall R, Braselmann H, Feuchtinger A, Molatore S, Lindner K, Walch A, Gross E, Schmitt M, Falkenberg N, Aubele M.
    BMC Cancer; 2016 Aug 08; 16():615. PubMed ID: 27502396
    [Abstract] [Full Text] [Related]

  • 2. Cyr61 and YB-1 are novel interacting partners of uPAR and elevate the malignancy of triple-negative breast cancer.
    Huber MC, Falkenberg N, Hauck SM, Priller M, Braselmann H, Feuchtinger A, Walch A, Schmitt M, Aubele M.
    Oncotarget; 2016 Jul 12; 7(28):44062-44075. PubMed ID: 27286449
    [Abstract] [Full Text] [Related]

  • 3. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R, Schaaf A.
    Int J Oncol; 2009 Jan 12; 34(1):15-23. PubMed ID: 19082473
    [Abstract] [Full Text] [Related]

  • 4. Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance.
    Andres SA, Edwards AB, Wittliff JL.
    J Clin Lab Anal; 2012 Feb 12; 26(2):93-103. PubMed ID: 22467324
    [Abstract] [Full Text] [Related]

  • 5. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
    Hildenbrand R, Schaaf A, Dorn-Beineke A, Allgayer H, Sütterlin M, Marx A, Stroebel P.
    Histol Histopathol; 2009 Jul 12; 24(7):869-77. PubMed ID: 19475533
    [Abstract] [Full Text] [Related]

  • 6. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
    Yoshizawa K, Nozaki S, Kitahara H, Kato K, Noguchi N, Kawashiri S, Yamamoto E.
    Oncol Rep; 2011 Dec 12; 26(6):1555-60. PubMed ID: 21833477
    [Abstract] [Full Text] [Related]

  • 7. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
    Bauer TW, Liu W, Fan F, Camp ER, Yang A, Somcio RJ, Bucana CD, Callahan J, Parry GC, Evans DB, Boyd DD, Mazar AP, Ellis LM.
    Cancer Res; 2005 Sep 01; 65(17):7775-81. PubMed ID: 16140945
    [Abstract] [Full Text] [Related]

  • 8. Down-regulation of uPA and uPAR by 3,3'-diindolylmethane contributes to the inhibition of cell growth and migration of breast cancer cells.
    Ahmad A, Kong D, Wang Z, Sarkar SH, Banerjee S, Sarkar FH.
    J Cell Biochem; 2009 Nov 01; 108(4):916-25. PubMed ID: 19693769
    [Abstract] [Full Text] [Related]

  • 9. Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - β1 (TGF-β1) and potential effects on migration and invasion.
    Magnussen SN, Hadler-Olsen E, Costea DE, Berg E, Jacobsen CC, Mortensen B, Salo T, Martinez-Zubiaurre I, Winberg JO, Uhlin-Hansen L, Svineng G.
    BMC Cancer; 2017 May 19; 17(1):350. PubMed ID: 28526008
    [Abstract] [Full Text] [Related]

  • 10. Relationships of protein biomarkers of the urokinase plasminogen activator system with expression of their cognate genes in primary breast carcinomas.
    Sereff SB, Daniels MW, Wittliff JL.
    J Clin Lab Anal; 2019 Nov 19; 33(9):e22982. PubMed ID: 31359505
    [Abstract] [Full Text] [Related]

  • 11. β-Catenin and NF-κB cooperate to regulate the uPA/uPAR system in cancer cells.
    Moreau M, Mourah S, Dosquet C.
    Int J Cancer; 2011 Mar 15; 128(6):1280-92. PubMed ID: 20473943
    [Abstract] [Full Text] [Related]

  • 12. Plasminogen Activation System in Rectal Adenocarcinoma.
    Razik E, Kobierzycki C, Grzegrzolka J, Podhorska-Okolow M, Drag-Zalesinska M, Zabel M, Dziegiel P.
    Anticancer Res; 2015 Nov 15; 35(11):6009-15. PubMed ID: 26504024
    [Abstract] [Full Text] [Related]

  • 13. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
    Xue A, Xue M, Jackson C, Smith RC.
    Int J Biochem Cell Biol; 2009 Nov 15; 41(8-9):1731-8. PubMed ID: 19433314
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB, Taylor M, Grøndahl-Hansen J, Kakolyris S, Gatter KC, Harris AL.
    J Pathol; 2001 Sep 15; 195(2):236-43. PubMed ID: 11592104
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.
    Pavón MA, Arroyo-Solera I, Céspedes MV, Casanova I, León X, Mangues R.
    Oncotarget; 2016 Aug 30; 7(35):57351-57366. PubMed ID: 27385000
    [Abstract] [Full Text] [Related]

  • 18. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
    Xue A, Scarlett CJ, Jackson CJ, Allen BJ, Smith RC.
    Pancreas; 2008 Mar 30; 36(2):160-7. PubMed ID: 18376307
    [Abstract] [Full Text] [Related]

  • 19. Targeting LC3 and Beclin-1 autophagy genes suppresses proliferation, survival, migration and invasion by inhibition of Cyclin-D1 and uPAR/Integrin β1/ Src signaling in triple negative breast cancer cells.
    Hamurcu Z, Delibaşı N, Geçene S, Şener EF, Dönmez-Altuntaş H, Özkul Y, Canatan H, Ozpolat B.
    J Cancer Res Clin Oncol; 2018 Mar 30; 144(3):415-430. PubMed ID: 29288363
    [Abstract] [Full Text] [Related]

  • 20. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
    Tecimer C, Doering DL, Goldsmith LJ, Meyer JS, Abdulhay G, Wittliff JL.
    Gynecol Oncol; 2001 Jan 30; 80(1):48-55. PubMed ID: 11136569
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.